As of now, there are no approved biosimilars for Humira (adalimumab) available in the United States. Humira is a biologic drug used to treat various autoimmune conditions such as rheumatoid arthritis, psoriasis, and Crohn's disease. Biosimilars are highly similar versions of biologic drugs that have been approved by regulatory authorities.

According to the information provided by Drug Patent Watch, as of October 2021, there are no approved biosimilars for Humira in the United States [1]. The website provides comprehensive information on drug patents, including biologics like Humira.

The U.S. Food and Drug Administration (FDA) is responsible for approving biosimilars in the United States. The FDA has a dedicated webpage providing information on biosimilar products, including product information, approval status, and regulatory guidance. According to the FDA's website, there are currently no approved biosimilars for Humira [2].

Additionally, GoodRx, a website that provides information on drug prices and discounts, confirms that there are no approved biosimilars for Humira available in the United States [3]. GoodRx also provides information on the cost of Humira and potential savings through discounts.

In conclusion, based on the provided sources, there are currently no approved biosimilars for Humira available in the United States. It is always advisable to consult with a healthcare professional for the most up-to-date information on available treatment options.

Sources:
[1] Drug Patent Watch. Humira. Retrieved from: https://www.drugpatentwatch.com/p/biologics/tradename/HUMIRA
[2] U.S. Food and Drug Administration. Biosimilar Product Information. Retrieved from: https://www.fda.gov/drugs/biosimilars/biosimilar-product-information
[3] GoodRx. Humira Biosimilars. Retrieved from: https://www.goodrx.com/humira/biosimilars